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Guidelines help physicians to make decisions in their
practice, but do not override the responsibility of health
professionals to make decisions and to follow the rules and
regulations applicable to drugs and devices. The level of
evidence and the strength of recommendation are outlined in
Tables 1 and 2.
The Czech Society of Cardiology endorses ESC guidelines
and prepares condensed summaries. For details and for
references see the original ESC document [1].
2 Introduction
Clinically relevant new aspects of 2014 version relate to:
(1) Predisposing factors for venous thromboembolism
(2) Simpliﬁcation of clinical prediction rules
(3) Age-adjusted D-dimer cut-offs
(4) Sub-segmental pulmonary embolism (PE)
(5) Incidental, clinically unsuspected PE
(6) Advanced risk stratiﬁcation of intermediate-risk PE
(7) Initiation of treatment with vitamin K antagonists
(8) The use of new oral anticoagulants
(9) Efﬁcacy and safety of reperfusion treatment for patients
at intermediate risk
(10) Early discharge and outpatient treatment of PE
(11) Current management of chronic thromboembolic pulmo-
nary hypertension
(12) Management of PE in pregnancy and in cancer patientsTable 1 – Classes of recommendations.
Classes of recommendations Deﬁn
Class I Evidence and/or general agreement t
is beneﬁcial, useful, effective.
Class II Conﬂicting evidence and/or diverging
efﬁcacy of the given treatment of pro
Class IIa Weight of evidence/opinion is in favour o
Class IIb Usefulness/efﬁcacy is less well establishe
Class III Evidence or general agreement that t
not useful/effective, and in some cas
Table 2 – Levels of evidence.
Level of evidence A Data derived from mu
Level of evidence B Data derived from a si
Level of evidence C Consensus of opinion 2.1 Epidemiology
Venous thromboembolism (VTE) encompasses deep vein
thrombosis (DVT) and pulmonary embolism (PE). It is the third
most frequent cardiovascular disease with an overall annual
incidence of 100–200 per 100,000 inhabitants. PE is a major cause
of mortality, morbidity, and hospitalization in Europe.
2.2 Predisposing factors
A list of predisposing (risk) factors for VTE is shown in Web
Table 1. The presence of persistent—as opposed to major,
temporary—risk factors may affect the decision on the
duration of anticoagulation therapy after a ﬁrst episode of PE.
2.3 Natural history
Following the acute PE episode, resolution of pulmonary
thrombi, as evidenced by lung perfusion defects, is frequently
incomplete. The incidence of conﬁrmed chronic thromboem-
bolic pulmonary hypertension (CTEPH) after unprovoked PE is
currently estimated at approximately 1.5%, with most cases
appearing within 24 months of the index event. The cumula-
tive proportion of patients with early recurrence of VTE (on
anticoagulant treatment) amounts to 2.0% at 2 weeks, 6.4% at 3
months and 8% at 6 months.
2.4 Pathophysiology
Acute PE interferes with both the circulation and gas exchange.
Right ventricular (RV) failure due to pressure overload is
considered the primary cause of death in severe PE. The abruptition Suggested wording to use
hat a given treatment or procedure Is recommended/is indicated
 opinion about the usefulness/
cedure.
f usefulness/efﬁcacy. Should be considered
d by evidence/opinion. May be considered
he given treatment or procedure is
es may be harmful.
Is not recommended
ltiple randomized clinical trials or meta-analyses.
ngle randomized clinical trial or large non-randomized studies.
of the experts and/or small studies, retrospective studies, registries.
Fig. 1 – Key factors contributing to haemodynamic collapse
in acute pulmonary embolism.
Fig. 2 – Initial risk stratification of acute PE.
Web Table 1 – Predisposing factors for VTE.
Strong risk factors (odds ratio >10)
Fracture of lower limb
Hospitalization for heart failure or atrial ﬁbrillation/ﬂutter (within
previous 3 months)
Hip or knee replacement
Major trauma
Myocardial infarction (within previous 3 months)
Previous venous thromboembolism
Spinal cord injury
Moderate risk factors (odds ratio 2–9)
Arthroscopic knee surgery
Auto–immune diseases
Blood transfusion
Central venous lines
Chemotherapy
Congestive heart or respiratory failure
Erythropoiesis-stimulating agents
Hormone replacement therapy (depends on formulation)
In vitro fertilization
Infection (speciﬁcally pneumonia, urinary tract infection or HIV)
Inﬂammatory bowel disease
Cancer (highest risk in metastatic disease)
Oral contraceptive therapy
Paralytic stroke
Postpartum period
Superﬁcial vein thrombosis
Thrombophilia
Weak risk factors (odds ratio <2)
Bed rest >3 days
Diabetes mellitus
Hypertension
Immobility due to sitting (e.g. prolonged car or air travel)
Increasing age
Laparoscopic surgery (e.g. cholecystectomy)
Obesity
Pregnancy
Varicose veins
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 2 7 5 – e 2 9 6e278increase in pulmonary vascular resistance results in RV
dilation, which alters the contractile properties of the RV
myocardium. The detrimental effects of acute PE on the RV
myocardium and the circulation are summarized in Fig. 1.
2.5 Clinical classiﬁcation of pulmonary embolism severity
The clinical classiﬁcation of the severity of an episode of acute
PE is based on the estimated PE-related early mortality risk
deﬁned by in-hospital or 30-day mortality (Fig. 2).
3 Diagnosis
3.1 Clinical presentation
PE may escape prompt diagnosis since the clinical signs and
symptoms are non-speciﬁc (Table 3). In most patients, PE is
suspected on the basis of dyspnoea, chest pain (requiring
differential diagnosis with acute coronary syndrome (ACS) or
aortic dissection), pre-syncope or syncope, and/or haemopty-
sis. Arterial hypotension and shock are rare but important
clinical presentations, since they indicate central PE and/or aseverely reduced haemodynamic reserve. Syncope is infre-
quent, but may occur regardless of the presence of haemo-
dynamic instability.
3.2 Assessment of clinical probability
Despite the limited sensitivity and speciﬁcity of individual
symptoms, signs, and common tests, the combination of
Table 4 – Clinical prediction rules for PE.
Items Clinical decision
rule points
Original
version
Simpliﬁed
version
Wells rule
Previous PE or DVT 1.5 1
Heart rate ≥100 b.p.m. 1.5 1
Surgery or immobilization
within the past four weeks
1.5 1
Haemoptysis 1 1
Active cancer 1 1
Clinical signs of DVT 3 1
Alternative diagnosis less likely than PE 3 1
Clinical probability
Three-level score
Low 0–1 N/A
Intermediate 2–6 N/A
High ≥7 N/A
Two-level score
PE unlikely 0–4 0–1
PE likely ≥5 ≥2
Revised Geneva Score
Previous PE or DVT 3 1
Heart rate
75–94 b.p.m. 3 1
≥95 b.p.m. 5 2
Surgery or fracture within the
past month
2 1
Haemoptysis 2 1
Active cancer 2 1
Unilateral lower limb pain 3 1
Pain on lower limb deep venous
palpation and unilateral oedema
4 1
Age >65 years 1 1
Clinical probability
Three-level score
Low 0–3 0–1
Intermediate 4–10 2–4
High ≥11 ≥5
Two-level score
PE unlikely 0–2 0–2
PE likely ≥6 ≥3
b.p.m. = beats per minute; DVT = deep vein thrombosis; PE = pul-
monary embolism.
Table 3 – Clinical characteristics of patients with
suspected PE in the emergency department.
Feature PE conﬁrmed
(n = 1880)
PE not conﬁrmed
(n = 528)
Dyspnoea 50% 51%
Pleuritic chest pain 39% 28%
Cough 23% 23%
Substernal chest pain 15% 17%
Fever 10% 10%
Haemoptysis 8% 4%
Syncope 6% 6%
Unilateral leg pain 6% 5%
Signs of DVT (unilateral
extremity swelling)
24% 18%
Adapted from Pollack et al. (2011).
DVT = deep vein thrombosis.
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 2 7 5 – e 2 9 6 e279ﬁndings evaluated by clinical judgement or by the use of
prediction rules allows to classify patients with suspected PE
into distinct categories of clinical or pre-test probability that
correspond to an increasing actual prevalence of conﬁrmed PE.
The most frequently used prediction rule is the one offered by
Wells et al. (Table 4). This rule has been validated extensively
using both a three-category scheme (low, moderate, or high
clinical probability of PE) and a two category scheme (PE likely
or unlikely). The revised Geneva rule is also simple and
standardized (Table 4).
3.3 D-dimer testing
The negative predictive value of D-dimer testing is high and a
normal D-dimer level renders acute PE or DVT unlikely (see
also Section 3.10.2). The positive predictive value of elevated D-
dimer levels is low and D-dimer testing is not useful for
conﬁrmation of PE. The quantitative enzyme-linked immuno-
sorbent assay (ELISA) have a diagnostic sensitivity of 95% or
better and can therefore be used to exclude PE in patients with
either a low or a moderate pre-test probability (Table 5). Recent
evidence suggests using age-adjusted cut-off values
(age  10 mg/l above 50 years) to improve the performance of
D-dimer testing in the elderly.
3.4 Computed tomographic pulmonary angiography
Computed tomographic angiography (MDCTA) has become the
method of choice for imaging the pulmonary vasculature in
patients with suspected PE. It allows adequate visualization ofTable 5 – Diagnostic yield of various D-dimer assays in exclud
Study D-dimer
assay
Pat
Carrier, 2009 (meta-analysis) Vidas Exclusion 56
Kearon, 2006; Wells, 2001 SimpliRed 20
Leclercq, 2003; ten Wolde, 2004; van Belle, 2006 Tinaquant 35
CI = conﬁdence interval; PE = pulmonary embolism.
a Low or intermediate clinical probability, or PE unlikely, depending on tthe pulmonary arteries down to at least the segmental level. In
patients with a low or intermediate clinical probability of PE as
assessed by the Wells rule, a negative MDCTA had a high
negative predictive value for PE (96% and 89%, respectively),ing acute PE according to outcome studies.
ients
n
PE
prevalence %
PE excluded by
D-dimer and clinical
probabilitya
n (%)
Three-month
thromboembolic
risk % (95% CI)
22 22 2246 (40) 0.1 (0.0–0.4)
56 12 797 (39) 0.0 (0.0–0.5)
08 21 1123 (32) 0.4 (0.0–1.0)
he studies.
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 2 7 5 – e 2 9 6e280whereas this was only 60% in those with a high pre-test
probability. Conversely, the positive predictive value of a
positive MDCTA was high (92–96%) in patients with an
intermediate or high clinical probability but much lower
(58%) in patients with a low pre-test likelihood of PE. Therefore,
clinicians should be particularly cautious in case of discor-
dance between clinical judgement and the MDCTA result. A
negative MDCTA is an adequate criterion for excluding PE in
patients with a non-high clinical probability of PE. MDCTA
showing PE at the segmental or more proximal level is
adequate proof of PE in patients with a non-low clinical
probability; however, the positive predictive value of MDCTA is
lower in patients with a low clinical probability of PE, and
further testing may be considered, especially if the clots are
limited to segmental or sub-segmental arteries.
3.5 Lung scintigraphy
Ventilation–perfusion scintigraphy (V/Q scan) is an estab-
lished diagnostic test for suspected PE. It is safe and few
allergic reactions have been described. The V/Q scan may
preferentially be applied in outpatients with low clinical
probability and a normal chest X-ray, in young (particularly
female) patients, in pregnancy, in patients with history of
contrast medium-induced anaphylaxis and strong allergic
history, in severe renal failure, and in patients with myeloma
and paraproteinaemia. Lung scan results are frequently classi-
ﬁed according to the criteria established in the PIOPED study:
normal or near-normal, low, intermediate (non-diagnostic), and
high probability of PE but a proposed classiﬁcation is preferable:
normal scan (excluding PE), high probability scan (considered
diagnostic of PE in most patients), and non-diagnostic scan.
Prospective clinical outcome studies suggested that it is safe to
withhold anticoagulant therapy in patients with a normal
perfusion scan. Performing only a perfusion scan is acceptable
in patients with a normal chest X-ray.
3.6 Pulmonary angiography
Pulmonary angiography is more often used to guide percuta-
neous catheter-directed treatment of acute PE.
3.7 Magnetic resonance angiography
This technique, although promising, is not yet ready for
clinical practice.
3.8 Echocardiography
Given the peculiar geometry of the RV, there is no individual
echocardiographic parameter that provides fast and reliable
information on RV size or function. Because of the reported
negative predictive value of 40–50%, a negative result cannot
exclude PE. On the other hand, signs of RV overload or
dysfunction may also be found in the absence of acute PE. RV
dilation is found in at least 25% of patients with PE, and its
detection, either by echocardiography or MDCTA, is useful for
risk stratiﬁcation of the disease. Echocardiographic examina-
tion is not recommended as part of the diagnostic work-up
in haemodynamically stable, normotensive patients withsuspected (not high-risk) PE. This is in contrast to suspected
high-risk PE, in which the absence of echocardiographic signs
of RV overload or dysfunction practically excludes PE as the
cause of haemodynamic instability. Mobile right heart thrombi
essentially conﬁrm the diagnosis of PE and their presence is
associated with RV dysfunction and high early mortality.
3.9 Compression venous ultrasonography
In the majority of cases, PE originates from DVT in a lower
limb. In a study using venography, DVT was found in 70% of
patients with proven PE. CUS shows a DVT in 30–50% of
patients with PE, and ﬁnding a proximal DVT in patients
suspected of having PE is considered sufﬁcient to warrant
anticoagulant treatment without further testing.
3.10 Diagnostic strategies
Table 6 provides the necessary evidence for alternative
evidence-based diagnostic algorithms.
3.10.1 Suspected pulmonary embolism with shock or
hypotension
The proposed strategy is shown in Fig. 3. Suspected high-risk
PE is an immediately life-threatening situation. The clinical
probability is usually high, and the differential diagnosis
includes acute valvular dysfunction, tamponade, acute coro-
nary syndrome (ACS), and aortic dissection. The most useful
initial test in this situation is bedside transthoracic echocar-
diography, which will yield evidence of acute pulmonary
hypertension and RV dysfunction. In a highly unstable patient,
echocardiographic evidence of RV dysfunction is sufﬁcient to
prompt immediate reperfusion without further testing. This
decision may be strengthened by the (rare) visualization of
right heart thrombi. Ancillary bedside imaging tests include
transoesophageal echocardiography which, if available, may
allow direct visualization of thrombi in the pulmonary artery
and its main branches, and bedside CUS, which can detect
proximal DVT. As soon as the patient can be stabilized by
supportive treatment, ﬁnal conﬁrmation of the diagnosis by
CT angiography should be sought.
3.10.2 Suspected pulmonary embolism without shock or
hypotension
Computed tomographic angiography has become the main
thoracic imaging test for investigating suspected PE (Fig. 4). In
patients admitted to the emergency department, plasma D-
dimer measurement, combined with clinical probability
assessment, is the logical ﬁrst step and allows PE to be ruled
out in around 30% of patients. D-dimer should not be
measured in patients with a high clinical probability. It is
also less useful in hospitalized patients because the number
needed to test to obtain a clinically relevant negative result is
high. MDCTA is the second-line test in patients with an
elevated D-dimer level and the ﬁrst-line test in patients with a
high clinical probability. CT angiography is considered to be
diagnostic of PE when it shows a clot at least at the segmental
level of the pulmonary arterial tree. Performing CUS before
MDCTA may be an option in patients with relative contra-
indications for CT such as in renal failure, allergy to contrast
Table 6 – Validated diagnostic criteria (based on non-invasive tests) for diagnosing PE in patients without shock or
hypotension according to clinical probability.
+/green = valid diagnostic criterion (no further testing required); S/red = invalid criterion (further testing mandatory); W/yellow = controversial
criterion (further testing to be considered).
a Low or intermediate probability lung scan according to the PIOPED classiﬁcation.
CT = computed tomographic; CUS = proximal lower limb venous ultrasonography; DVT = deep vein thrombosis; PE = pulmonary embolism;
PIOPED = Prospective Investigation of Pulmonary Embolism Diagnosis; V/Q scan = ventilation–perfusion scintigram.
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readily available, it remains a valid option for patients with an
elevated D-dimer and a contraindication to MDCTA. V/Q
scintigraphy may be preferred over MDCTA to avoid unneces-
sary radiation, particularly in younger and female patients in
whom thoracic CT may raise the lifetime risk of breast cancer.
3.11 Areas of uncertainty
The diagnostic value and clinical signiﬁcance of sub-segmen-
tal defects on MDCTA are still under debate. The value and
cost-effectiveness of CUS in suspected PE should be further
clariﬁed. Finally, 'triple rule-out' (for coronary artery disease,
PE and aortic dissection) CT angiography for patients present-
ing with nontraumatic chest pain appears to be accurate for
the detection of coronary artery disease.
4 Prognostic assessment
4.1 Clinical parameters
PE severity index (PESI; Table 7) is the most extensively
validated score to date. A simpliﬁed version—sPESI has beendeveloped and validated. Clinical symptoms and signs of acute
RV failure (e.g. persistent arterial hypotension and cardiogenic
shock) indicate a high risk of early death. Further, syncope and
tachycardia, as well as clinical parameters related to pre-
existing conditions and comorbidity, are associated with an
unfavourable short-term prognosis.
4.2 Imaging of the right ventricle by echocardiography or
computed tomographic angiography
Echocardiographic ﬁndings used to risk stratify patients with
PE include RV dilation, an increased RV–LV diameter ratio,
hypokinesia of the free RV wall, increased velocity of the jet of
tricuspid regurgitation, decreased tricuspid annulus plane
systolic excursion, or combinations of the above.
RV dysfunction detected by echocardiography is associated
with increased short-term mortality in patients without
haemodynamic instability, but its overall positive predictive
value is low (Table 8). Right-to-left shunt through a patent
foramen ovale and the presence of right heart thrombi are
associated with increased mortality in patients with acute PE.
MDCTA may detect RV enlargement as an indicator of RV
dysfunction and prognosis (Table 8).
Fig. 3 – Proposed diagnostic algorithm for patients with suspected high-risk PE, i.e. presenting with shock or hypotension.
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4.3.1 Markers of right ventricular dysfunction
A meta-analysis found that 51% of 1132 unselected patients
with acute PE had elevated BNP or NT-proBNP concentrations
on admission. These patients had a 10% risk of early death and
a 23% risk of an adverse clinical outcome. In normotensive
patients with PE, the positive predictive value of elevated BNP
or NT-proBNP for early mortality is low (Table 8). Low levels of
BNP or NT-proBNP can identify patients with a favourable
short-term clinical outcome based on their high negative
predictive value.
4.3.2 Markers of myocardial injury
A meta-analysis (1985 patients) showed elevated cardiac
troponin concentrations in approximately 50% of PE patients
(Table 8). Elevated troponin concentrations were associated
with high mortality both in unselected patients and in
haemodynamically stable patients; however, other reportshave suggested a limited prognostic value of elevated
troponins in normotensive patients. Negative predictive
value of troponins is high. Heart-type fatty acid-binding
protein (H-FABP) was also found to possess prognostic value
in acute PE.
4.3.3 Other (non-cardiac) laboratory biomarkers
Elevated serum creatinine levels and a decreased glomerular
ﬁltration rate are related to 30-day all-cause mortality in acute
PE. Elevated neutrophil gelatinase-associated lipocalin (NGAL)
and cystatin C are also of prognostic value. Elevated D-dimer
concentrations were associated with increased short-term
mortality, while levels <1500 ng/mL had a negative predictive
value of 99% for excluding three-month all-cause mortality.
4.4 Combined modalities and scores
Various combinations of clinical ﬁndings with imaging and
laboratory tests have been proposed and tested in an attempt
Fig. 4 – Proposed diagnostic algorithm for patients with suspected not high-risk pulmonary embolism.
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remains to be determined.
4.5 Prognostic assessment strategy (recommendation I)
For prediction of early (in-hospital or 30-day) outcome in
patients with acute PE, both the PE-related risk and theRecommendations I – (for prognostic assessment).
Recommendations 
Initial risk stratiﬁcation of suspected or conﬁrmed PE—based on the pres
recommended to identify patients at high risk of early mortality.
In patients not at high risk, use of a validated clinical risk prediction sco
considered to distinguish between low- and intermediate-risk PE.
In patients at intermediate risk, assessment of the right ventricle with e
injury using a laboratory biomarker, should be considered for further r
CT = computed tomographic (pulmonary angiography); PE = pulmonary e
ﬁed pulmonary embolism severity index.
a Class of recommendation.
b Level of evidence.patient's clinical status and comorbidities should be taken into
consideration (Table 9). The risk-adjusted therapeutic strate-
gies and algorithms recommended on the basis of this
classiﬁcation are discussed in the following section and
summarized in Fig. 5. Further—see recommendations I.
Around one-third of PE patients are at low risk of an early
adverse outcome (PESI Class I or II, or sPESI of 0). NormotensiveClassa Levelb
ence of shock or persistent hypotension—is I B
re, preferably the PESI or sPESI, should be IIa B
chocardiography or CT, and of myocardial
isk stratiﬁcation.
IIa B
mbolism; PESI = pulmonary embolism severity index; sPESI = simpli-
Table 7 – Original and simplified PESI.
Parameter Original version Simpliﬁed version
Age Age in years 1 point (if age >80 years)
Male sex +10 points –
Cancer +30 points 1 point
Chronic heart failure +10 points 1 point
Chronic pulmonary disease +10 points
Pulse rate ≥110 b.p.m. +20 points 1 point
Systolic blood pressure <100 mm Hg +30 points 1 point
Respiratory rate >30 breaths per minute +20 points –
Temperature <36 8C +20 points –
Altered mental status +60 points –
Arterial oxyhaemoglobin saturation <90% +20 points 1 point
Risk strataa
Class I: ≤65 points 0 points = 30-day mortality risk 1.0%
Very low 30-day mortality risk (0–1.6%) (95% CI 0.0–2.1%)
Class II: 66–85 points ≥1 point(s) = 30-day mortality risk 10.9%
Low mortality risk (1.7–3.5%) (95% CI 8.5–13.2%)
Class III: 86–105 points
Moderate mortality risk (3.2–7.1%)
Class IV: 106–125 points
High mortality risk (4.0–11.4%)
Class V: >125 points
Very high mortality risk (10.0–24.5%)
b.p.m. = beats per minute; PESI = pulmonary embolism severity index.
a Based on the sum of points.
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constitute an intermediate-risk group and further risk assess-
ment should be considered. Patients with both RV dysfunction
and elevated troponin should be classiﬁed into an intermedi-
ate-high-risk category.
5 Treatment in the acute phase
5.1 Haemodynamic and respiratory support
Acute RV failure with resulting low cardiac index (CI) is the
leading cause of death in patients with high-risk PE. Aggressive
volume expansion is of no beneﬁt, but modest (500 mL) ﬂuidRecommendations II – (for acute phase treatment).
Recommendations 
PE with shock or hypotension (high-risk)
It is recommended that intravenous anticoagulation with UFH should be i
high-risk PE.
Thrombolytic therapy is recommended. 
Surgical pulmonary embolectomy is recommended for patients in whom
Percutaneous catheter-directed treatment should be considered as an al
embolectomy for patients in whom full-dose systemic thrombolysis is
PE = pulmonary embolism; UFH = unfractionated heparin.
a Class of recommendation.
b Level of evidence.
c If appropriate expertise and resources are available on site.challenge may increase CI. Norepinephrine should probably be
limited to hypotensive patients. The use of dobutamine and/or
dopamine may be considered for patients with low CI, and
normal blood pressure (BP). Epinephrine combines the
beneﬁcial properties of norepinephrine and dobutamine,
without the systemic vasodilatory effects of the latter.
According to data from small clinical studies, inhalation of
nitric oxide may improve the haemodynamic status and gas
exchange of patients with PE. Preliminary data suggest that
levosimendan may restore right ventricular–pulmonary arte-
rial coupling by combining pulmonary vasodilation with an
increase in RV contractility.
Positive intrathoracic pressure induced by mechanical
ventilation may reduce venous return and worsen RV failure;Classa Levelb
nitiated without delay in patients with I C
I B
 thrombolysis is contraindicated or has failed.c I C
ternative to surgical pulmonary
 contraindicated or has failed.c
IIa C
Recommendations III – (for acute phase treatment).
Recommendations Classa Levelb
PE without shock or hypotension (intermediate-or low-risk)c
Anticoagulation: combination of parenteral treatment with VKA
Initiation of parenteral anticoagulation is recommended without delay in patients with high or intermediate clinical
probability of PE while diagnostic work-up is in progress.
I C
LMWH or fondaparinux is the recommended form of acute phase parenteral anticoagulation for most patients. I A
In parallel to parenteral anticoagulation, treatment with a VKA is recommended, targeting an INR of 2.5 (range 2.0–3.0). I B
Anticoagulation: new oral anticoagulants
As an alternative to the combination of parenteral anticoagulation with a VKA, anticoagulation with rivaroxaban (15 mg
twice daily for 3 weeks, followed by 20 mg once daily) is recommended.
I B
As an alternative to the combination of parenteral anticoagulation with a VKA, anticoagulation with apixaban (10 mg
twice daily for 7 days, followed by 5 mg twice daily) is recommended.
I B
As an alternative to VKA treatment, administration of dabigatran (150 mg twice daily, or 110 mg twice daily for patients
≥80 years of age or those under concomitant verapamil treatment) is recommended following acute phase parenteral
anticoagulation.
I Bd
As an alternative to VKA treatment, administration of edoxabang is recommended following acute-phase parenteral
anticoagulation.
I B
New oral anticoagulants (rivaroxaban, apixaban, dabigatran, edoxaban) are not recommended in patients with severe
renal impairment.e
III A
Reperfusion treatment
Routine use of primary systemic thrombolysis is not recommended in patients not suffering from shock or hypotension. III B
Close monitoring is recommended in patients with intermediate-high risk PE to permit early detection of
haemodynamic decompensation and timely initiation of 'rescue' reperfusion therapy.
I B
Thrombolytic therapy should be considered for patients with intermediate-high-risk PE and clinical signs of
haemodynamic decompensation.
IIa B
Surgical pulmonary embolectomy may be considered in intermediate-high-risk patients if the anticipated risk of
bleeding under thrombolytic treatment is high.f
IIb C
Percutaneous catheter-directed treatment may be considered in intermediate-high-risk patients if the anticipated risk of
bleeding under thrombolytic treatment is high.f
IIb B
Early discharge and home treatment
Patients with acute low-risk PE should be considered for early discharge and continuation of treatment at home if proper
outpatient care and anticoagulant treatment can be provided.
IIa B
aPTT = activated partial thromboplastin time; INR = international normalized ratio; LMWH = low-molecular-weight heparin; PE = pulmonary
embolism; UFH = unfractionated heparin; VKA = vitamin K antagonist.
a Class of recommendation.
b Level of evidence.
c See Table 9 for deﬁnition of the risk categories.
d RE-COVER and RE-COVER II are considered one large trial.
e Creatinine clearance <30 mL/min for rivaroxaban, dabigatran and edoxaban; and <25 mL/min for apixaban.
f If appropriate expertise and resources are available on site.
g Caution: Edoxaban is currently subject to regulatory review for the treatment of venous thromboembolism in the European Union.
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with caution. Low tidal volumes (approximately 6 mL/kg lean
body weight) should be used in an attempt to keep the end-
inspiratory plateau pressure <30 cm H2O.
Experimental evidence, occasional case reports and patient
series suggest that extracorporeal cardiopulmonary support
can be an effective procedure in massive PE.
5.2 Anticoagulation (recommendations II and III)
The objective is to prevent both early death and recurrent
symptomatic or fatal PE. The standard duration of antic-
oagulation is at least 3 months (also see Section 6). Acute-
phase consists of administering parenteral anticoagulation
[unfractionated heparin (UFH), low-molecular weight hepa-
rin (LMWH) or fondaparinux] over the ﬁrst 5–10 days.
Parenteral heparin should overlap with the initiation of
a vitamin K antagonist (VKA); alternatively, it can befollowed by administration of dabigatran or edoxaban.
The treatment with rivaroxaban or apixaban should be
started directly or after a 1–2 day administration of UFH,
LMWH or fondaparinux.
5.2.1 Parenteral anticoagulation
In patients with high or intermediate clinical probability for PE
(see Section 3), parenteral anticoagulation should be initiated
whilst awaiting the results of diagnostic tests. Subcutaneous
LMWH or fondaparinux are preferred, as they carry a lower risk
of inducing major bleeding and heparin-induced thrombocy-
topenia (HIT). On the other hand, UFH is recommended for
patients in whom primary reperfusion is considered, as well as
for those with creatinine clearance <30 mL/min, or severe
obesity. LMWHs approved for the treatment of acute PE are
listed in Table 10. LMWH and fondaparinux need no routine
monitoring, but periodic measurement of anti-Xa levels may
be considered during pregnancy.
Table 8 – Imaging and laboratory testsa for prediction of earlyb mortality in acute PE.
Test or biomarker Cut-off value Sensitivity,
(95% CI)
Speciﬁcity,
(95% CI)
NPV
(95% CI)
PPV
(95% CI)
OR or HR
(95% CI)
No. of
patients
Study design
(reference)
Remarks
Echocardiography Various criteria
of RV dysfunction
74 (61–84) 54 (51–56) 98 (96–99) 8 (6–10) 2.4 (1.3–4.3) 1249 Metaanalysis RV dysfunction on
echocardiography or CT was one
of the inclusion criteria in two
randomized trials investigating
thrombolysis in normotensive
patients with PE.
CT angiography RV/LV ≥ 1.0 46 (27–66) 59 (54–64) 93 (89–96) 8 (5–14) 1.5 (0.7–3.4) 383 Metaanalysis
RV/LV ≥ 0.9 84 (65–94) 35 (30–39) 97 (94–99) 7 (5–10) 2.8 (0.9–8.2) 457 Prospective cohort
BNP 75–100 pg/m 85 (64–95) 56 (50–62) 98 (94–99) 14 (9–21) 6.5 (2.0–21) 261 Metaanalysis The optimal cut-off value for PE
has not been deﬁned.
NT-proBNP 600 pg/mL 86 (69–95) 50 (46–54) 99 (97–100) 7 (5–19) 6.3 (2.2–18.3) 688 Prospective cohorte NT-proBNP <500 pg/mL was one
of the inclusion criteria in a
single-armed management trial
investigating home treatment of
PE.
Troponin I Different assays/
cut-off valuesc
NR NR NR NR 4.0 (2.2–7.2) 1303 Metaanalysis A positive cardiac troponin test
was one of the inclusion criteria
in a randomized trial
investigating thrombolysis in
normotensive patients with PE.
Troponin T Different assays/
cut-off valuesc
NR NR NR NR 682 Metaanalysis
14 pg/mLd 87 (71–95) 42 (38–47) 98 (95–99) 9 (6–12) 5.0 (1.7–14.4) 526 Prospective cohorte
H-FABP 6 ng/mL 89 (52–99) 82 (74–89) 99 (94–99) 28 (13–47) 36.6 (4.3–304) 126 Prospective cohorte
BNP = brain natriuretic peptide; CT = computed tomographic; H-FABP = heart-type fatty acid-binding protein; HR = hazard ratio; LV = left ventricular; NPV = negative predictive value; NR = not reported
in the reference cited; NT-proBNP = N-terminal pro-brain natriuretic peptide; OR = odds ratio; PE = pulmonary embolism; PPV = positive predictive value; RV = right ventricular.
a The table shows the results of meta-analyses or, in the absence thereof, of the largest prospective cohort studies.
b In most studies, 'early' refers to the in-hospital period or the ﬁrst 30 days after the index event.
c In the studies included in this meta-analysis, cut-off values for the cardiac troponin tests used corresponded to the 99th percentile of healthy subjects with a coefﬁcient variation of <10%.
d High-sensitivity assay.
e These studies included only normotensive patients and used a combined outcome (all-cause death or major cardiovascular complications).
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Table 9 – Classification of patients with acute PE based on early mortality risk.
PE = pulmonary embolism; PESI = Pulmonary embolism severity index; RV = right ventricular; sPESI = simpliﬁed Pulmonary embolism severity
index.
a PESI Classes III–V indicate moderate to very high 30-day mortality risk; sPESI ≥1 point(s) indicate high 30-day mortality risk.
b Echocardiographic criteria of RV dysfunction include RV dilation and/or an increased end-diastolic RV–LV diameter ratio (in most studies, the
reported threshold value was 0.9 or 1.0); hypokinesia of the free RV wall; increased velocity of the tricuspid regurgitation jet; or combinations of
the above. On computed tomographic (CT) angiography (four-chamber views of the heart), RV dysfunction is deﬁned as an increased end-
diastolic RV/LV (left ventricular) diameter ratio (with a threshold of 0.9 or 1.0).
c Markers of myocardial injury (e.g. elevated cardiac troponin I or -T concentrations in plasma), or of heart failure as a result of (right)
ventricular dysfunction (elevated natriuretic peptide concentrations in plasma).
d Neither calculation of the PESI (or sPESI) nor laboratory testing are considered necessary in patients with hypotension or shock.
e Patients in the PESI Classes I–II, or with sPESI of 0, and elevated cardiac biomarkers or signs of RV dysfunction on imaging tests, are also to be
classiﬁed into the intermediate-low-risk category.
This might apply to situations in which imaging or biomarker results become available before calculation of the clinical severity index.
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VKA should be initiated as soon as possible, preferably the same
day as the parenteral anticoagulant. Anticoagulation with UFH,
LMWH, or fondaparinux should be continued for at least 5 days
and until the international normalized ratio (INR) has been 2.0–
3.0 for two consecutive days. Warfarin can be started at a dose of
10 mg in younger (<60 years of age), otherwise healthy
outpatients, and at a dose of 5 mg in older and hospitalized
patients. Pharmacogenetic testing does not improve the quality
of anticoagulation. Dosing based on the patient's clinical data is
possibly superior to ﬁxed loading regimens.
5.2.3 New oral anticoagulants
The results of the trials using NOACs in the treatment of VTE
(Table 11) indicate that these agents are non-inferior (in terms
of efﬁcacy) and possibly safer (particularly in terms of major
bleeding) than the standard heparin/VKA regimen. At the
moment of publication of these guidelines, rivaroxaban,
dabigatran and apixaban are approved for treatment of VTE
in the European Union.
5.3 Thrombolytic treatment
Thrombolytic treatment of acute PE restores pulmonary
perfusion more rapidly than anticoagulation. The approved
regimens for PE are shown in Web Table 3. Most contra-
indications to thrombolysis (Web Table 4) should be consid-
ered relative in patients with life-threatening, high-risk PE.
UFH infusion should be stopped during administration of
streptokinase or urokinase; it can be continued during rtPAinfusion. It appears reasonable to continue anticoagulation
with UFH for several hours after the end of thrombolytic
treatment before switching to LMWH or fondaparinux.
Thrombolysis can still be useful in patients who have had
symptoms up to 14 days.
In the absence of haemodynamic compromise, the clinical
beneﬁts of thrombolysis have remained controversial for
many years. Pulmonary Embolism Thrombolysis (PEITHO) trial
was a multicentre, randomized, double-blind comparison of
tenecteplase plus heparin vs. placebo plus heparin in acute PE
patients with RV dysfunction and positive troponin. The
primary efﬁcacy outcome, a composite of all-cause death or
haemodynamic decompensation/collapse within 7 days of
randomization, was signiﬁcantly reduced with tenecteplase
(2.6% vs. 5.6% in the placebo group; P < 0.015; OR 0.44; 95% CI
0.23–0.88). The beneﬁt of thrombolysis was mainly driven by a
signiﬁcant reduction in the rate of haemodynamic collapse
(1.6% vs. 5.0%; P < 0.002).
Analysis of pooled data from trials using various throm-
bolytic agents and regimens reported intracranial bleeding
rates between 1.9% and 2.2%.
5.4 Surgical embolectomy
Multidisciplinary teams have recently reintroduced the
concept of surgical embolectomy for high-risk PE, and also
for selected patients with intermediate-high-risk PE, partic-
ularly if thrombolysis is contraindicated or has failed.
Surgical embolectomy has also been successfully performed
in patients with right heart thrombi straddling the
Fig. 5 – Risk-adjusted management strategies in acute PE (see Table 9 for definition of the risk categories).
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Preoperative thrombolysis increases the risk of bleeding,
but it is not an absolute contraindication to surgical
embolectomy.5.5 Percutaneous catheter-directed treatment
For patients with absolute contraindications to thrombolysis,
interventional treatment options include (i) thrombus
Table 10 – Low-molecular-weight heparins and penta-
saccharide (fondaparinux) approved for the treatment of
pulmonary embolism.
Dosage Interval
Enoxaparin 1.0 mg/kg
or
1.5 mg/kga
Every 12 h
Once dailya
Tinzaparin 175 U/kg Once daily
Dalteparin 100 IU/kgb
or
200 IU/kgb
Every 12 hb
Once dailyb
Nadroparinc 86 IU/kg
or
171 IU/kg
Every 12 h
Once daily
Fondaparinux 5 mg (body weight <50 kg)
7.5 mg (body weight 50–100 kg)
10 mg (body weight >100 kg)
Once daily
All regimens administered subcutaneously.
IU = international units; LMWH = low-molecular-weight heparin.
a Once-daily injection of enoxaparin at the dosage of 1.5 mg/kg is
approved for inpatient (hospital) treatment of PE in the United
States and in some, but not all, European countries.
b In cancer patients, dalteparin is given at a dose of 200 IU/kg body
weight (maximum, 18 000 IU) once daily over a period of 1month,
followed by 150 IU/kg once daily for 5 months. After this period,
anticoagulation with a vitamin K antagonist or an LMWH should be
continued indeﬁnitely or until the cancer is considered cured.
c Nadroparin is approved for treatment of PE in some, but not all,
European countries.
Web Table 3 – Approved thrombolytic regimens for
pulmonary embolism.
Streptokinase 250 000 IU as a loading dose over 30 min,
followed by 100 000 IU/h over 12–24 h
Accelerated regimen: 1.5 million IU over 2 h
Urokinase 4400 IU/kg as a loading dose over 10 min,
followed by 4400 IU/kg per hour over 12–24 h
Accelerated regimen: 3 million IU over 2 h
rtPA 100 mg over 2 h; or
0.6 mg/kg over 15 min (maximum dose 50 mg)
IU = international units; rtPA = recombinant tissue plasminogen
activator.
Web Table 4 – Contraindications to thrombolytic therapy.
Absolute contraindicationsa
 Haemorrhagic stroke or stroke of unknown origin at any time
 Ischaemic stroke in the preceding 6 months
 Central nervous system damage or neoplasms
 Recent major trauma/surgery/head injury in the preceding
3 weeks
 Gastrointestinal bleeding within the last month
 Known bleeding risk
Relative contraindications
 Transient ischaemic attack in the preceding 6 months
 Oral anticoagulant therapy
 Pregnancy, or within one week postpartum
 Non-compressible puncture site
 Traumatic resuscitation
 Refractory hypertension (systolic blood pressure >180 mm Hg)
 Advanced liver disease
 Infective endocarditis
 Active peptic ulcer
a Absolute contraindications to thrombolysis might become rela-
tive in a patient with immediately life-threatening high-risk PE.
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thrombectomy with hydrodynamic catheter devices, (iii)
suction thrombectomy with aspiration catheters and (iv)
rotational thrombectomy. On the other hand, for patients
without absolute contraindications to thrombolysis, catheter-
directed (eventually ultrasound accelerated) thrombolysis or
pharmacomechanical thrombolysis are preferred approaches
(see also Ref. [2]).
A review on interventional treatment included 35 non-
randomized studies covering 594 patients.
5.6 Venous ﬁlters (recommendations IV)
There are no data to support the routine use of venous ﬁlters in
patients with free-ﬂoating thrombi in the proximal veins.
There is also no evidence to support the use of IVC ﬁlters in
patients scheduled for systemic thrombolysis, surgical embo-
lectomy, or pulmonary thromboendarterectomy.Recommendations IV – (for venous filters).
Recommendations 
IVC ﬁlters should be considered in patients with acute PE and absolute c
IVC ﬁlters should be considered in case of recurrence of PE, despite ther
Routine use of IVC ﬁlters in patients with PE is not recommended. 
IVC = inferior vena cava; PE = pulmonary embolism.
a Class of recommendation.
b Level of evidence.5.7 Early discharge and home treatment
Crucial issue is to select patients with low risk of an adverse
early outcome. Low-risk patients in the PESI Class I or II, and
probably those with sPESI of 0 (Table 9), should be considered
for early discharge and outpatient treatment. Table 12
summarizes recent multicentre trials that investigated the
three-month clinical outcome of patients who were dis-
charged early or treated entirely as outpatients. The ﬁrst
one was terminated prematurely because of an increased
short-term mortality rate (2.8%, 2 patients) in the early-
discharge arm. In the second larger trial, there was one
non-VTE related death in each treatment group (0.6%). In aClassa Levelb
ontraindications to anticoagulation. IIa C
apeutic levels of anticoagulation. IIa C
III A
Table 11 – Overview of phase III clinical trials with non-vitamin K-dependent new oral anticoagulants (NOACs) for the acute-phase treatment and standard duration of
anticoagulation after VTE.
Drug Trial Design Treatments and dosage Duration Patients Efﬁcacy outcome (results) Safety outcome (results)
Dabigatran RE-COVER Double-blind,
double-dummy
Enoxaparin/dabigatran
(150 mg b.i.d.)a vs.
enoxaparin/warfarin
6 months 2539 patients
with acute VTE
Recurrent VTE or fatal
PE: 2.4% under dabigatran
vs. 2.1% under warfarin
Major bleeding: 1.6% under
dabigatran vs. 1.9% under
warfarin
RE-COVER II Double-blind,
double-dummy
Enoxaparin/dabigatran
(150 mg b.i.d.)a vs.
enoxaparin/warfarin
6 months 2589 patients
with acute VTE
Recurrent VTE or fatal
PE: 2.3% under dabigatran
vs. 2.2% under warfarin
Major bleeding: 15 patients
under dabigatran vs. 22
patients under warfarin
Rivaroxaban EINSTEINDVT Open-label Rivaroxaban (15 mg b.i.d.
for 3 weeks, then 20 mg o.d.)
vs. enoxaparin/warfarin
3, 6, or
12 months
3449 patients
with acute DVT
Recurrent VTE or fatal
PE: 2.1% under rivaroxaban
vs. 3.0% under warfarin
Major or CRNM bleeding
8.1% under rivaroxaban vs.
8.1% under w
EINSTEIN-PE Open-label Rivaroxaban (15 mg b.i.d.
for 3 weeks, then 20 mg o.d.)
vs. enoxaparin/warfarin
3, 6, or
12 months
4832 patients
with acute PE
Recurrent VTE or fatal
PE: 2.1% under rivaroxaban
vs. 1.8% under warfarin
Major or CRNM bleeding:
10.3% under rivaroxaban vs.
11.4% under warfarin
Apixaban AMPLIFY Double-blind,
double-dummy
Apixaban (10 mg b.i.d.
for 7 days, then 5 mg b.i.d.)
vs. enoxaparin/warfarin
6 months 5395 patients
with acute DVT or PE
Recurrent VTE or fatal
PE: 2.3% under apixaban
vs. 2.7% under warfarin
Major bleeding: 0.6% under
apixaban vs. 1.8% under
warfarin
Edoxaban Hokusai-VTE Double-blind,
double-dummy
LMWH/edoxaban
(60 mg o.d.; 30 mg o.d.
if creatinine clearance 30–50 mL/min
or body weight <60 kg) vs. UFH
or LMWH/warfarin
Variable,
3–12 months
8240 patients
with acute DVT
and/or PE
Recurrent VTE or fatal
PE: 3.2% under edoxaban
vs. 3.5% under warfarin
Major or CRNM bleeding:
8.5% under edoxaban vs.
10.3% under warfarin
b.i.d. = bis in die (twice daily); CRNM = clinically relevant non-major; DVT = deep vein thrombosis; o.d. = omni die (once daily); PE = pulmonary embolism; UFH = unfractionated heparin; VTE = venous
thromboembolism.
a Approved doses of dabigatran are 150 mg b.i.d. and 110 mg b.i.d.
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Table 12 – Design of recent multicentre trials on home treatment of acute PE.
Author Design Inclusion criteria Main exclusion criteria Patients Treatment
Aujesky Open-label
Randomized
Non-inferiority
19 centres (ED)
Discharge within
24 h vs. inpatient
therapy
Age ≥18 years
Conﬁrmed acute PE
PESI Class I or II
BP <100 mm Hg
Pain needing opioids
Active bleeding or high risk
Extreme obesity
CrCl <30 mL/min
HIT history
Barriers to home treatment
344 (of 1557
screened)
Both arms: enoxaparin
s.c. twice daily; overlap
with VKA
(starting 'early')
Otero Open-label
Randomized
9 centres
Discharge after 3–5 days vs.
inpatient therapy
Age ≥18 years
Conﬁrmed acute PE
Low-risk by Uresandi
clinical prediction rule350
Haemodynamic instability
Troponin T ≥0.1 ng/mL
RV dysfunction (TTE)
High bleeding risk
Severe comorbidity
O2 saturation <93%
COPD, asthma
Extreme obesity
132 (of 1016
screened)
Both arms: LMWH
s.c. overlap with VKA
(starting day 10)
Zondag Prospective cohort
12 centres (ED)
All treated as
outpatients, discharge
within 24 hours
Age ≥18 years
Conﬁrmed acute PE
Haemodynamic instability
Active bleeding or high risk
Oxygen requirement
CrCl <30 mL/min
Hepatic failure
HIT history
Barriers to home treatment
297 (of 581
screened)
Nadroparin s.c.
once daily; overlap
with VKA
(starting day 1)
Agterof Prospective cohort
5 centres (ED)
Discharge within 24 h
Age ≥18 years
Conﬁrmed acute PE
NT-proBNP
<500 pg/mL
Haemodynamic instability
Active bleeding or high risk
Severe comorbidity
Pain with i.v. analgesia
Oxygen requirement
Creatinine >150 mmol/L
Barriers to home treatment
152 (of 351
screened)
LMWH s.c. once
daily; overlap with
VKA (starting 'early')
BP = (systolic) blood pressure; COPD = (severe) chronic obstructive pulmonary disease; CrCl = creatinine clearance; ED = emergency department
(s); HIT = heparin-induced thrombocytopenia; i.v. = intravenous; LMWH = low-molecular-weight heparin; NT-proBNP = N-terminal pro-brain
natriuretic peptide; PE = pulmonary embolism; PESI = Pulmonary embolism severity index (see Table 7); RV = right ventricular; s.c.
= subcutaneous; TTE = transthoracic echocardiography; VKA = vitamin K antagonist.
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 2 7 5 – e 2 9 6 e291meta-analysis of 14 (mostly cohort-) studies, the pooled
incidences of recurrent VTE, major bleeding and total
mortality did not differ signiﬁcantly between outpatients,
patients discharged early, and those treated as inpatients.
5.8 Therapeutic strategies
An algorithm and principles of the recommended therapeutic
strategies for acute PE are shown in Fig. 5 and recommenda-
tions II+III.
5.9 Areas of uncertainty
Further trials and investigation are necessary for risk
stratiﬁcation in not-high-risk patients with PE, for postulation
of therapeutic strategy in intermediate-high-risk PE, and for
creation of the criteria for early discharge and home treatment
of low-risk patients with PE.
6 Duration of anticoagulation
(recommendation V)
The aim of anticoagulant treatment in patients with PE is to
prevent VTE. Clinical trials evaluating duration of anticoagulanttreatment showed, that patients with PE should receive at
least 3 months of anticoagulant treatment. The risk of
recurrent VTE after withdrawal of anticoagulant treatment
after 3, 6 or 12 months is similar. Indeﬁnite treatment reduces
the risk of recurrence of VTE by about 90%, but this reduction
is accompanied by a 1% or higher annual risk of major
bleeding.
Active cancer is a major risk factor for recurrence of VTE. At
least 3–6 months of treatment with LMWH is recommended
for patients with VTE and cancer and after ﬁrst 6 months
treatment with LMWH or VKA is recommended as long as the
disease is considered active.
The risk for recurrent VTE after discontinuation of
anticoagulant treatment in patients with provoked PE is
approximately 2.5% per year.
The risk for recurrent VTE after discontinuation of
anticoagulant treatment in patients with unprovoked PE is
approximately 4.5% per year. Indeﬁnite anticoagulation
therapy should be considered for patients with a ﬁrst
unprovoked proximal DVT or PE and for patients with lupus
anticoagulant, deﬁcit of protein C and S, with homozygous
factor V Leiden and homozygous prothrombin G20210A. The
option to withdraw anticoagulant treatment should periodically
be re-assessed. Lifelong treatment is recommended for most
patients with second unprovoked DVT or PE. Therapy with
Recommendations V – (for duration of anticoagulation after pulmonary embolism).
Recommendations Classa Levelb
For patients with PE secondary to a transient (reversible) risk factor, oral anticoagulation is recommended
for 3 months.
I B
For patients with unprovoked PE, oral anticoagulation is recommended for at least 3 months. I A
Extended oral anticoagulation should be considered for patients with a ﬁrst episode of unprovoked PE and
low bleeding risk.
IIa B
Anticoagulation treatment of indeﬁnite duration is recommended for patients with a second episode of
unprovoked PE.
I B
Rivaroxaban (20 mg once daily), dabigatran (150 mg twice daily, or 110 mg twice daily for patients ≥80 years of
age or those under concomitant veracious treatment) or apixaban (2.5 mg twice daily) should be considered as
an alternative to VKA (except for patients with severe renal impairment) if extended anticoagulation treatment
is necessary.c
IIa Bd
In patients who receive extended anticoagulation, the risk–beneﬁt ratio of continuing such treatment should be
reassessed at regular intervals.
I C
In patients who refuse to take or unable to tolerate any form of oral anticoagulants, aspirin may be considered
for extended secondary VTE prophylaxis.
IIb B
For patients with PE and cancer, weight adjusted subcutaneous LMWH should be considered for the ﬁrst 3–6 months. IIa B
For patients with PE and cancer, extended anticoagulation (beyond the ﬁrst 3–6 months) should be considered for an
indeﬁnite period or until the cancer is cured.
IIa C
LMWH = low-molecular-weight heparin; PE = pulmonary embolism; VKA = vitamin K antagonist.
a Class of recommendation.
b Level of evidence.
c Long-term data on patients taking new oral anticoagulants for secondary PE prophylaxis are not yet available.
d B refers to the evidence available for each drug separately.
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 2 7 5 – e 2 9 6e292aspirin after termination of oral anticoagulation could particu-
larly reduce the risk of recurrence (recommendations V).
6.1 New oral anticoagulants for extended treatment
Three NOACs (dabigatran, rivaroxaban, and apixaban) have
been evaluated in the extended treatment in patients with
VTE. The results are in line with the studies that tested NOACs
in the acute phase treatment and standard duration of
anticoagulation after PE or VTE. They indicate that NOACs
are both effective (in terms of prevention of symptomatic or
fatal recurrence of VTE) and probably safer than standard VKA
regimens (recommendations V and Table 13).
7 Chronic thromboembolic pulmonary
hypertension
7.1 Epidemiology
Chronic thromboembolic pulmonary hypertension (CTEPH) is
a distinct subgroup of PH caused by chronic obstruction of
pulmonary arteries. CTEPH may occur in approximately ﬁve
individuals per million population per year.
7.2 Pathophysiology
CTEPH is primarily caused by pulmonary thromboembolism.
Clinical history of VTE is reported in 80% of patients with CTEPH.
CTEPH does not share the same risk factor proﬁle with VTE and
has been associated with only a few speciﬁc thrombophilic
factors (presence of lupus anticoagulant, antiphospholipid
antibodies and elevated level of factor VIII). In addition,
splenectomy, ventriculoatrial shunt for hydrocephalus therapy,
inﬂammatory bowel disease, and chronic osteomyelitis areassociated with a higher incidence of CTEPH. Apart from major
pulmonary vascular obstruction, the pathophysiology of CTEPH
includes a pulmonary microvascular disease.
7.3 Clinical presentation and diagnosis
The median age of patients at diagnosis of CTEPH is 63 years,
both genders are equally affected. Clinical symptoms and
signs are non-speciﬁc or absent in early CTEPH. The diagnosis
of CTEPH is based on ﬁndings obtained after at least 3 months
of effective anticoagulation (mean pulmonary arterial pres-
sure ≥25 mm Hg, pulmonary arterial wedge pressure ≤15 mm
Hg, at least one perfusion defect detected by V/Q scintigraphy,
or detected pulmonary artery obstruction). V/Q lung scintigra-
phy remains the main ﬁrst-line imaging modality for CTEPH.
MDCTA alone cannot rule out the disease. The ﬁnal step in the
diagnostic pathway is right heart catheterization and selective
pulmonary angiography (Fig. 6).
7.4 Treatment and prognosis (recommendation VI)
Pulmonary endarterectomy (PEA) under deep hypothermia
and circulatory arrest is the treatment of choice. The majority
of patients experience substantial relief from symptoms and
near-normalization of haemodynamics after the surgery.
General criteria of operability include pre-operative New York
Heart Association functional class II–IV and the surgical
accessibility of thrombi.
Balloon pulmonary angioplasty could be an alternative for
selected patients with non-operable CTEPH.
Routine cava ﬁlter placement is not justiﬁed by the
available evidence.
Optimal medical treatment for CTEPH consists of lifelong
anticoagulants (no data exist on the efﬁcacy and safety of
NOACs), diuretics, and oxygen.
Table 13 – Clinical trials on extended treatment of venous thromboembolism.
Study Activea Design Comparator Expected
reduction
Treatment
duration
No. patients
enrolled
VTE in control
group
Risk reduction
for recurrent VTE
Major or
CRNM bleeding
in activea group
RE-SONATE Dabigatran
150 mg b.i.d.c
Placebo Superiority 70% 6 months 1343 5.6% 92% 5.3%
RE-MEDY Dabigatran
150 mg b.i.d.c
Warfarin
(INR 2–3)
Noninferiority Absolute
increase, <2.8
18–36 months 2856 1.3% Risk difference,
0.38% vs. VKA
5.6% (vs. 10.2% in
warfarin arm)
EINSTEIN Ext Rivaroxaban
20 mg daily
Placebo Superiority 70% 6–12 months 1196 7.1% 82% 6.0%
AMPLIFY Ext Apixaban
5.0 mg b.i.d.
Placebo Superiority 41% 12 months 2486 8.8% 80% 4.2%
Apixaban
2.5 mg b.i.d.d
81% 3.0%
WARFASA Aspirin Placebo Superiority 40% ≥24 months 402 11.2%b 40% 1.0%b
ASPIRE Aspirin Placebo Superiority 30% 4 years (actual,
27 months)
822 6.5%b 26% 1.7%b
b.i.d. = bis in die (twice daily); CRNM = clinically relevant non-major; SD = standard deviation; VKA = vitamin K antagonists; VTE = venous thromboembolism.
a 'Active' denotes in the Table the direct oral thrombin or factor Xa inhibitor (or aspirin) tested; the comparator arm also received anticoagulation (a vitamin K antagonist) in some of the studies.
b Incidence per patient-year.
c Approved doses of dabigatran are 150 mg b.i.d. and 110 mg b.i.d.
d This is the approved dose of apixaban for extended treatment.
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Fig. 6 – Algorithm for the diagnosis of chronic
thromboembolic pulmonary hypertension.
Adapted from Lang et al. (2010). Fig. 7 – Algorithm for the treatment of chronic
thromboembolic pulmonary hypertension.
Adapted from Ghofrani et al. (2013).
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the rationale for use of drugs approved for pulmonary arterial
hypertension in inoperable patients and in patients with
persistent or residual pulmonary hypertension after PEA. Only
riociguat (oral stimulator of soluble guanylate cyclase)
received approval for use in this indication (Fig. 7 and
recommendations VI).
8 Speciﬁc problems
8.1 Pregnancy (recommendation VII)
PE is the leading cause of pregnancy-related maternal death in
developed countries.
The risk of PE is higher in the post-partum period,
particularly after a caesarean section.8.1.1 Diagnosis
Exposure of the foetus to ionizing radiation is a concern when
investigating suspected PE (Table 14).
The usual D-dimer cut-off value should apply to rule out PE
in pregnancy. If the D-dimer result is abnormal, diagnostic
work-up may continue with lower-limb CUS (since proximal
DVT warrants anticoagulation and makes thoracic imaging
unnecessary). If ultrasonography is negative, the diagnosis
should be pursued. A perfusion scan and MDCTA are equally
safe for ruling out PE in pregnancy. Lung scintigraphy may be
preferred over MDCTA because it avoids the high radiation
dose delivered to the female breast (Table 14).
8.1.2 Treatment
The treatment of PE in pregnancy is based on heparin
anticoagulation. Treatment should consist of a weight-
adjusted dose of LMWH. Adaptation according to anti-Xa
Recommendations VI – (for chronic thromboembolic pulmonary hypertension).
Recommendations Classa Levelb
In PE survivors with persistent dyspnoea, diagnostic evaluation for CTEPH should be considered. IIa C
Screening for CTEPH in asymptomatic survivors of PE is currently not recommended. III C
It is recommended that, in all patients with CTEPH, the assessment of operability and decisions regarding other
treatment strategies be made by a multidisciplinary team of experts.
I C
Life-long anticoagulation is recommended in all patients with CTEPH. I C
Surgical PEA is recommended for patients with CTEPH. I C
Riociguat is recommended in symptomatic patients who have been classiﬁed as having inoperable CTEPH by a CTEPH
team including at least one experienced PEA surgeon, or have persistent/recurrent CTEPH after surgical treatment.
I B
Off-label use of drugs approved for PAH may be considered in symptomatic patients who have been classiﬁed as
having inoperable CTEPH by a CTEPH team including at least one experienced PEA surgeon.
IIb B
CTEPH = chronic thromboembolic pulmonary hypertension; PE = pulmonary embolism; PEA = pulmonary endarterectomy.
a Class of recommendation.
b Level of evidence.
Table 14 – Estimated radiation absorbed in procedures used for diagnosing PE.
Test Estimated foetal
radiation exposure (mSv)
Estimated maternal radiation exposure
to breast tissue (mSv)
Chest X-ray <0.01 0.01
Perfusion lung scan with technetium-99 m labelled albumin
Low dose: 40 MBq 0.11–0.20 0.28–0.50
High dose: 200 MBq 0.20–0.60 1.20
Ventilation lung scan 0.10–0.30 <0.01
Computed tomographic angiography 0.24–0.66 10–70
Adapted from Bajc et al. (2009) and Chunilal et al. (2009).
mSv = milisievert; PE = pulmonary embolism.
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 2 7 5 – e 2 9 6 e295monitoring may be considered in women at extremes of body
weight or with renal disease.
Unfractionated heparin is not contraindicated in pregnan-
cy. Fondaparinux should not be used in pregnancy due to the
lack of data. VKAs and NOACs are contraindicated in pregnant
patients.
After delivery, heparin treatment may be replaced by VKAs
and it should be administered for at least 6 weeks after delivery
and with a minimum overall treatment duration of 3 months.
VKAs can be given to breast-feeding mothers.
The risk of complications of thrombolytic treatment for the
mother may be similar to that in the non-pregnant population.
It should not be used peripartum, except for critical cases
(recommendations VII).Recommendations VII – (for pulmonary embolism in pregnanc
Recommendations 
Suspicion of PE in pregnancy warrants formal diagnostic assessment wi
D-dimer measurement may be performed in order to avoid unnecessary i
clinical signiﬁcance as in non-pregnant patients.
Venous compression ultrasonography may be considered in order to avo
proximal DVT conﬁrms PE.
Perfusion scintigraphy may be considered to rule out suspected PE in pr
CT angiography should be considered if the chest X-ray is abnormal or i
A weight-adjusted dose of LMWH is the recommended therapy during pregna
CT = computed tomographic; DVT = deep vein thrombosis; LMWH = low 
a Class of recommendation.
b Level of evidence.8.2 Pulmonary embolism and cancer (recommendation
VIII)
The overall risk of venous thromboembolism in cancer
patients is four times as great as in the general population.
Patients receiving chemotherapy have a six-fold increase in
the adjusted risk ratio for VTE compared with a healthy
population, prophylactic anticoagulation is not routinely
recommended. The risk of VTE increases over 90-fold in the
ﬁrst 6 weeks after cancer surgery. Continued vigilance is
therefore necessary, as currently recommended prophylactic
anticoagulation covers only 30 days after cancer surgery
(recommendations VIII).y).
Classa Levelb
th validated methods. I C
rradiation, as a negative result has a similar IIb C
id unnecessary irradiation, as a diagnosis of IIb C
egnant women with normal chest X-ray. IIb C
f lung scintigraphy is not readily available. IIa C
ncy in patients without shock or hypotension. I B
molecular weight heparin; PE = pulmonary embolism.
Recommendations VIII – (for pulmonary embolism in cancer).
Recommendations Classa Levelb
Incidental PE in patients with cancer should be managed in the same manner as symptomatic PE. IIa C
Negative D-dimer levels have the same negative diagnostic value as in non-cancer patients. IIa B
For patients with PE and cancer, weight-adjusted subcutaneous LMWH should be considered for the ﬁrst 3–6 months. IIa B
For patients with PE and cancer, extended anticoagulation (beyond the ﬁrst 3–6 months) should be considered for an
indeﬁnite period or until the cancer is cured.
IIa C
LMWH = low molecular weight heparin; PE = pulmonary embolism.
a Class of recommendation.
b Level of evidence.
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Non-thrombotic PE can be caused by different cell types or
by bacteria, fungi, parasites, foreign materials, and gas.
Symptoms are similar to those of acute VTE. Diagnosis of
non-thrombotic PE can be a challenge (microemboli cannot
be detected on CT and images and clinical evidence is
limited).
8.3.1 Septic embolism
Septic embolism is commonly associated with right-sided
endocarditis. Staphylococcus aureus is the most common
pathogen, the incidence of anaerobic gram positive and
-negative bacteria, bacteroides species, and fungi is increasing.
8.3.2 Foreign-material pulmonary embolism
The incidence of foreign-material PE is increasing due to use of
interventional techniques in modern medicine. The material
may cause further thrombosis and sepsis.
8.3.3 Fat embolism
Pulmonary involvement in fat embolism is not only due to
vascular obstruction but also to the release of substances
triggering an inﬂammatory cascade. In most cases the
condition is self-limiting. Treatment is supportive.
8.3.4 Air embolism
Venous air embolization is often an iatrogenic complication of
the manipulation of venous catheters. The lethal volume of air
after injection in humans is estimated to range from 100 to
500 mL. CT scanning is the most sensitive diagnostic test.
Treatment includes maintenance of the circulation, preven-
tion of further entry of gas, volume expansion, left lateral
decubitus position and administration of oxygen.8.3.5 Amniotic ﬂuid embolism
Estimated incidences range between 1.9 and 2.5 cases per
100 000 maternities. Mortality is high (up to 21%). Management
is supportive.
8.3.6 Tumour embolism
Pulmonary intravascular tumour emboli are seen in up to 26%
of autopsies of patients with solid malignancies. Tumour
microembolism may mimic many lung conditions, macro-
embolism is indistinguishable from VTE. Treatment should
target the underlying malignant disease.
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